Rafael Holdings, Inc.

Rafael Holdings, Inc.

RFL
Rafael Holdings, Inc.US flagNew York Stock Exchange
1.37
USD
-0.02
- -
50.35MMarket Cap
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.44
0.44
0.35
0.37
0.31
0.05
0.02
0.01
0.03
- -
0.03
Basic EPS, GAAP
0.06
0.01
-0.92
-0.35
-0.65
-1.46
-6.22
-0.08
-1.43
- -
-0.92
Free Cash Flow per Basic Share
-0.12
-0.27
-0.2
-0.26
-0.33
-0.94
-1.3
-0.48
-0.33
- -
-0.46
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
3.96
-0.08
-0.42
-1.01
-2.42
-8.24
-7.4
-8.37
- -
-8.84
Tangible Book Value per Share
- -
4.88
9
9.15
8.06
8.06
4.77
4.21
3.31
- -
0.95
Basic Weighted Avg Shares
13
13
13
13
16
17
20
23
24
29
25
Sales/Revenue/Turnover
6
6
4
5
5
1
- -
- -
1
- -
1
Operating Margin (%)
21.33
3.93
-87.87
-135.79
-172.4
-2,643.27
-14,750.49
-5,391.76
-16,110.99
- -
-2,348.5
Depreciation Expense
2
2
2
2
2
- -
- -
- -
- -
- -
- -
Net Income, GAAP
1
- -
-12
-5
-10
-25
-125
-2
-34
- -
-23
Effective Tax Rate (%)
38.74
32.35
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
12.7
2.46
-266.51
-95.17
-212.12
-3,060.35
-30,404.39
-672.4
-5,401.88
- -
-3,127.6
Working Capital
- -
12
44
12
4
-3
87
81
65
- -
31
LT Debt
- -
- -
- -
15
- -
- -
- -
- -
- -
- -
- -
Total Equity
- -
62
116
125
131
137
97
97
86
- -
85
Return on Invested Capital (%)
- -
0.48
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
0.46
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
0.55
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Oct'25
Jan'25
Apr'25
ST Debt
2
2
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
25
25
32
Market Capitalization
45
50
39

Working Capital

FRC

in mil. unless spec.
Oct'25
Jan'25
Apr'25
Total Current Assets
70
66
42
Cash, Cash Equivalents & STI
54
48
38
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
7
7
11
Payables & Accruals
5
4
10
ST Debt
2
2
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.15
0.25
-1.34
-0.18
-1.43
2025
-0.35
-0.19
-0.19
- -
- -
2026
-0.19
-0.13
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Howard S. Jonas
Full Time Employees
28
Sector
Real Estate
Industry
Real Estate - Services
Address
520 Broad Street Newark NJ United States of America 07102
IPO Date
Mar 27, 2018
Business
Rafael Holdings, Inc. (NYSE:RFL) is a clinical-stage biotechnology holding company that invests in and develops therapies for difficult-to-treat diseases, including novel cancer metabolism inhibitors and treatments for rare genetic disorders; it operates through healthcare, infusion technology, and real estate segments with activities in the United States and Israel. Founded in 2017 and headquartered in Newark, New Jersey, the company holds a 100% interest in Cyclo Therapeutics, LLC, which advances Trappsol Cyclo (hydroxypropyl-beta-cyclodextrin) in the fully enrolled Phase 3 TransportNPC trial for Niemann-Pick Disease Type C1, with 48-week interim data expected mid-2025; it maintains investments in Cornerstone Pharmaceuticals developing CPI-613 (devimistat) for solid tumors and acute myeloid leukemia, LipoMedix Pharmaceuticals with liposome-delivered oncology therapies, Day Three Labs reimagining cannabis products via pharmaceutical-grade technology like Unlokt, Rafael Medical Devices for orthopedic instruments, and commercial real estate assets. In March 2025, Rafael Holdings completed its merger with Cyclo Therapeutics following shareholder approval, integrating the rare disease asset and shifting strategic focus toward its commercialization while curtailing early-stage development; the company closed a $25 million rights offering in June 2025 to fund Trappsol Cyclo advancement, issued 1,078,796 warrants expiring December 2025 as part of the merger, and announced CEO Bill Conkling's transition amid strengthened emphasis on Trappsol Cyclo, with recent abstracts accepted for presentation at the 15th International Congress of Inborn Errors of Metabolism and preliminary Phase 3 sub-study data showing stabilization in young NPC1 patients.

Company News

APIChat
  • Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer's Disease”

  • Critical Comparison: Elite Pharmaceuticals (OTCMKTS:ELTP) versus Rafael (NYSE:RFL)

  • Keurig Dr Pepper Acquires JDE Peet's and Announces Rafael Oliveira as CEO of Future Global Coffee Co.

  • Keurig Dr Pepper Acquires JDE Peet's and Announces Rafael Oliveira as CEO of Future Global Coffee Co.

  • Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

  • T3 Defense Brings in Former Rafael and Avnon Leadership to Lead Business Operations

  • Analyzing Rafael (NYSE:RFL) & 60 Degrees Pharmaceuticals (NASDAQ:SXTP)

  • Mt. San Rafael Hospital Selects Oracle Health To Optimize Financial Performance, Enhance Patient Care

  • Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

  • R2S receives $1.25 billion Tamir production contract for facility in Camden, Arkansas

  • Terra Clean Closes the Acquisition of the Past Producing Uranium Claims in San Rafael Swell, Utah, United States

  • Terra Clean Closes the Acquisition of the Past Producing Uranium Claims in San Rafael Swell, Utah, United States

  • Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

  • Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

  • Update: Terra Clean Energy Corp. Enters into Definitive Agreements  to Acquire Uranium Claims on The San Rafael Swell, Utah, United States

  • Terra Clean Energy Corp. Enters into Definitive Agreements to Acquire Uranium Claims on The San Rafael Swell, Utah, United States

  • Terra Clean Energy Corp. Enters into Definitive Agreements to Acquire Uranium Claims on the San Rafael Swell, Utah, United States

  • Terra Clean Energy Corp. Announces Agreement to Earn 100% Interest in 75 Past Producing Uranium Claims on The San Rafael Swell, Utah, United States

  • Terra Clean Energy Corp. Announces Agreement to Earn 100% Interest in 75 Past Producing Uranium Claims on The San Rafael Swell, Utah, United States

  • Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old